2 results
Approved WMOCompleted
Primary:* To determine the effect of vedolizumab IV compared to adalimumab SC on clinical remission at Week 52.Secondary:* To evaluate the effect of vedolizumab IV compared to adalimumab SC on mucosal healing at Week 52.* To evaluate the effect of…
Approved WMOCompleted
Evaluate the effect of tedalinab on ECG parameters, CNS Function and Pain Perception in Healthy Subjects.